Table 1.
Summary of equilibrium (Day 3–28) TFV and TFV-DP concentrations during implant use.
| Implant, analyte, matrixa units |
n | % Quantifiable | Median (IQR)b |
|---|---|---|---|
|
Low, TFV, plasma nM ng mL-1 |
10 | 70c |
183.5 (12.4–253.1) 52.7 (4.2–72.7) |
|
Low, TFV-DP, PBMC nM fmol/106 cells |
15 | 100 |
772.9 (387.8–4,306) 154.6 (77.6–861.1) |
|
Low, TFV, dermal tissue fmol mg-1 ng mg-1 |
15 | 100 |
82.6 × 103 (57.0 × 103–415.0 × 103) 23.7 (16.4–119.2) |
|
Low, TFV-DP, dermal tissue fmol mg-1 |
15 | 100 | 1.448 (518.6–2.429) |
|
High, TFV, plasma nM ng mL-1 |
15 | 100 |
1.070 (673.5–1.695) 307.4 (193.5–486.8) |
|
High, TFV-DP, PBMC nM fmol/106 cells |
15 | 100 |
14,987 (8.784–21,531) 2.997 (1.757–4.306) |
|
High, TFV, dermal tissue fmol mg-1 ng mg-1 |
15 | 100 |
540.1 × 103 (292.1 × 103–1.156 × 103) 155.1 (83.9–332.1) |
|
High, TFV-DP, dermal tissue fmol mg-1 |
15 | 100 | 6.303 (2.351–8.846) |
Low, 0.28 mg d-1 TAF release in vivo; high, 0.58 mg d-1 TAF release in vivo.
aAll values correspond to time points (D3-28) with the implant in place.
bInterquartile range, between first (25th percentile) and third (75th percentile) quartiles.
cBLQ values were omitted from the analysis.